Glycopyrrolate/indacaterol - Orion
Alternative Names: Indacaterol-glycopyrronium - Orion; New dry-powder inhaler / indacaterol-glycopyrronium - OrionLatest Information Update: 28 Jan 2024
Price :
$50 *
At a glance
- Originator Orion
- Class Antiasthmatics; Antispasmodics; Bronchodilators; Indans; Pyrrolidines; Quaternary ammonium compounds; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Finland (Inhalation, Powder)
- 01 Oct 2021 Glycopyrrolate/indacaterol - Orion is available for licensing as of 01 Oct 2021. https://www.orion.fi/en/Orion-group/about-orion/partnering/
- 19 Jul 2021 Orion stopped development of glycopyrrolate/indacaterol new dry powder inhaler in Chronic obstructive pulmonary disease in Finland